Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study-Reference-Cited by-同舟云学术

Discovery of an Oral Respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a Human RSV Challenge Study

Published:2015-01-27 Issue:4 Volume:58 Page:1630-1643
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Mackman Richard L.¹,Sangi Michael¹,Sperandio David¹,Parrish Jay P.¹,Eisenberg Eugene¹,Perron Michel¹,Hui Hon¹,Zhang Lijun¹,Siegel Dustin¹,Yang Hai¹,Saunders Oliver¹,Boojamra Constantine¹,Lee Gary¹,Samuel Dharmaraj¹,Babaoglu Kerim¹,Carey Anne¹,Gilbert Brian E.²,Piedra Pedro A.²,Strickley Robert¹,Iwata Quynh¹,Hayes Jaclyn¹,Stray Kirsten¹,Kinkade April¹,Theodore Dorothy¹,Jordan Robert¹,Desai Manoj¹,Cihlar Tomas¹

Affiliation:

1. Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404, United States

2. Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm5017768

Reference37 articles.

1. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

2. Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States